Clinical trials: Systemic Lupus
Lupus Arthritis
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis
The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules (0.5 milligrams [mg] and 1 mg) in participants with active lupus arthritis.
- Trial name
- NCT01085084
- Testing
- Laquinimod
- Where
- 22 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Systemic Lupus Erythematosus, Lupus
Aerobic Exercise in Women With Systemic Lupus Erythematosus
Background: As many as 1.5 million Americans are living with systemic lupus erythematosus (Lupus). Lupus makes people very tired. It also makes it hard for people to be physically active.
- Conditions
- Systemic Lupus Erythematosus, Lupus, Autoimmune Disease, Rheumatic Disease
- Trial name
- NCT03186794
- Testing
- Treadmill exercise training
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Systemic Lupus Erythematosus
Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
This study will be conducted to assess the safety, tolerability, and immunogenicity of repeat doses of BOS161721 (20 milligrams [mg], 60 mg, and 120 mg) administered subcutaneously in adult participants with moderately to…
- Trial name
- NCT03371251
- Testing
- BOS161721
- Where
- 68 sites in United States, Argentina and 10 more
- Volunteers
- 143 people
- Sponsor
- Boston Pharmaceuticals
Lupus Nephritis
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules in active lupus nephritis participants.
- Trial name
- NCT01085097
- Testing
- Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 46 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
HIV Infections, Systemic Lupus Erythematosus
Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
The purpose of this study is to evaluate the breadth and potency of HIV-1 neutralizing antibody (nAb) responses and examine the safety and tolerability of an HIV gp120 protein vaccine (AIDSVAX® B/E) in HIV-uninfected adults…
- Trial name
- NCT03618056
- Testing
- AIDSVAX® B/E
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches
This is a randomized, double blind, placebo controlled trial of abatacept for the treatment of lupus arthritis and other manifestations of lupus.
- Trial name
- ABC (NCT02270957)
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Oklahoma Medical Research Foundation
Systemic Lupus Erythematosus (SLE), Juvenile SLE
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
No drug treatment is completely free of risk and lack of response, adverse events and poor adherence may affect its effectiveness.
- Conditions
- Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus
- Trial name
- NCT03122431
- Testing
- Thalidomide, Hydroxychloroquine reduced, standard dose of HCQ
- Where
- Brazil
- Volunteers
- 93 people
- Sponsor
- University of Sao Paulo General Hospital
Systemic Lupus Erythematosus
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Background: Lupus causes a person s immune system to attack the body. It can cause blood vessel problems, heart attack, or stroke. Researchers want to see if the drug pioglitazone may help.
- Trial name
- NCT02338999
- Testing
- PET/CT, Pioglitazone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Lupus Erythematosus
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).
- Trial name
- EMBRACE (NCT01632241)
- Testing
- Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Where
- 96 sites in United States, Brazil and 4 more
- Volunteers
- 503 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Systemic Lupus Erythematosus (SLE)
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
- Trial name
- NCT02804763
- Testing
- Dapirolizumab pegol (DZP)
- Where
- 71 sites in United States, Bulgaria and 11 more
- Volunteers
- 182 people
- Sponsor
- UCB Biopharma S.P.R.L.
Systemic Lupus Erythematosus Arthritis
Abatacept for SLE Arthritis (IM101-330)
This research trial is for patients who have been diagnosed with systemic lupus erythematosus (SLE) with swollen, tender joints (which is called inflammatory polyarthritis) because of the SLE.
- Trial name
- NCT02429934
- Testing
- abatacept also known as Orencia also known as CTLA4-Ig
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of California, Los Angeles
Systemic Lupus Erythematosus
A Phase II Study of M2951 in SLE
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus…
- Trial name
- NCT02975336
- Testing
- M2951
- Where
- 157 sites in United States, Argentina and 17 more
- Volunteers
- 469 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lupus Nephritis
Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients with active lupus nephritis.
- Trial name
- BLISS-LN (NCT01639339)
- Testing
- Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Where
- 118 sites in United States, Argentina and 19 more
- Volunteers
- 448 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Systemic Lupus Erythematosus
A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus.
- Trial name
- NCT02660944
- Testing
- RSLV-132
- Where
- 16 sites in United States
- Volunteers
- 64 people
- Sponsor
- Resolve Therapeutics
Congenital Heart Block, Neonatal Lupus
Preventive Approach to Congenital Heart Block With Hydroxychloroquine
Women with antibodies to proteins called SSA/Ro and or SSB/La face a 2% chance of having a child with a life threatening heart condition regardless of whether they have very active lupus, are in remission, or have only vague…
- Conditions
- Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block
- Trial name
- PATCH (NCT01379573)
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- NYU Langone Health
Lupus Erythematosus, Systemic
Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
This study will examine a new approach to treating patients with severe systemic lupus erythematosus (SLE) that involves collecting stem cells (cells produced by the bone marrow that develop into blood cells) from the patient…
- Trial name
- NCT00076752
- Testing
- fludarabine phosphate, cyclophosphamide, Rituxan (rituximab)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Systemic Lupus Erythematosus
Triptorelin for Ovary Protection in Childhood Onset Lupus
The purpose of this study is to test the safety of triptorelin when used for the protection of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for systemic lupus erythematosus (SLE; lupus) and to…
- Trial name
- NCT00124514
- Testing
- Triptorelin pamoate
- Where
- 10 sites in United States, Brazil
- Volunteers
- 31 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Systemic Lupus Erythematosus
Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects
This is an open-label, randomized, parallel group, single dose study in healthy Chinese subjects. The purpose of this study is to characterize the pharmacokinetic profile and safety profile of 200 mg single dose of belimumab…
- Trial name
- NCT04136145
- Testing
- Belimumab for IV, Belimumab for SC
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Lupus Nephritis, Systemic Lupus Erythematosus
A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)
This is a Phase III, randomized, double-blind, placebo-controlled, multicentre, parallel-group study designed to evaluate the efficacy and safety of ocrelizumab added to SOC (corticosteroid plus one of two immunosuppressant…
- Trial name
- BELONG (NCT00626197)
- Testing
- Corticosteroids, Cyclophosphamide, Mycophenolate Mofetil
- Volunteers
- 381 people
- Sponsor
- Genentech, Inc.
Lupus Erythematosus, Systemic
An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who have completed Study GA30044 (NCT02908100) up to…
- Trial name
- NCT03407482
- Testing
- GDC-0853
- Where
- 53 sites in United States, Argentina and 9 more
- Volunteers
- 160 people
- Sponsor
- Genentech, Inc.